Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$1.40M$1.40Mno prior Q2 2019 on file Net Income$582.09K$582.09KN/M vs Q2 2019 EPS Diluted$0.01$0.01N/M vs Q2 2019 Operating Income$13,840N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin1.0%
Net margin41.6%
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end